Cardiac MRI parametric mapping: clinical workflow and interpretation

This is a familiar point of frustration for clinicians: the map looks precise, but the interpretation still depends on context.

Cardiac MRI parametric mapping adds quantitative tissue measurements to the familiar anatomical and contrast-enhanced images. Used carefully, it can help identify diffuse myocardial abnormalities that are difficult to appreciate from regional signal contrast alone. The practical task is to connect each measurement to the clinical question, the local scanner protocol, and the rest of the examination.

Start with the tissue question

Before reviewing a map, I ask what tissue process the study is intended to assess. Is the concern myocardial edema or acute injury? Diffuse fibrosis? An infiltrative process? The answer guides which parameters matter and how much weight to give them.

Parametric mapping measures tissue properties on a pixel-by-pixel basis. T1, T2, and T2* are reported in milliseconds; extracellular volume, or ECV, is reported as a percentage. These measurements provide quantitative information across the myocardium rather than relying only on differences in signal between one region and another.

That distinction is useful when an abnormality is diffuse. If the whole myocardium is affected, a regional comparison may offer little contrast. Mapping gives the reader another way to assess the tissue, although it does not independently name the disease or replace the rest of the MRI examination.

In my clinic, I frame the maps as pieces of evidence with different sensitivities to tissue change:

• Native T1 provides a quantitative tissue measurement before contrast administration. Abnormal values can support the presence of myocardial tissue alteration, but they are not specific to one cause.
• T2 mapping assesses tissue water content and is particularly relevant when edema or acute injury is part of the clinical question.
• T2\* is another quantitative relaxation measurement, with interpretation dependent on the clinical indication and the local acquisition method.
• ECV estimates the extracellular space as a proportion of myocardial tissue, using both pre- and post-contrast measurements and the patient’s hematocrit.

A result becomes clinically useful when it agrees with the history, ventricular function, other MRI findings, and the suspected disease process. When those pieces do not agree, the mismatch is a reason to review acquisition and context before assigning a diagnosis.

A map supplies a measurement; the clinical question determines what that measurement can tell you.

T1, T2, and T2*: what the numbers represent

Native T1 and myocardial fibrosis

T1 mapping measures the longitudinal relaxation time of myocardial tissue and expresses it in milliseconds. Native T1 is acquired without contrast. It can contribute to the assessment of diffuse myocardial disease, including fibrosis, but a raised value should not be treated as a fibrosis diagnosis by itself. T1 may change with more than one tissue process, and the sequence, scanner, field strength, and heart rate all influence the result.

That is why I encourage clinicians to read native T1 alongside late gadolinium enhancement, ventricular structure and function, and the patient’s clinical presentation. A focal enhancement pattern and a diffuse change in native T1 answer related but different questions. One does not automatically confirm or cancel the other.

For a suspected diffuse process, a normal-looking conventional image does not make a quantitative map irrelevant. Conversely, an abnormal map without a coherent clinical or imaging pattern deserves caution. The value is a signal to interpret, not a verdict.

T2 mapping and edema

T2 mapping quantifies a tissue property associated with water content. It has diagnostic utility in settings where myocardial edema and acute injury are suspected, including acute myocarditis and acute cardiac allograft rejection. In practical terms, it can help determine whether the myocardium shows evidence consistent with an active tissue response.

Timing matters. An edema-sensitive measurement is most informative when interpreted in relation to symptom onset, treatment, and the rest of the examination. A T2 value should not be detached from those factors and read as a standalone marker of a particular diagnosis.

T2* and the role of acquisition context

T2* is also expressed in milliseconds, but it is a distinct measurement from T2. The two should not be casually substituted for one another in a report or a clinical discussion. As with the other maps, interpretation depends on the acquisition and the question being asked.

The useful habit is to confirm exactly which parameter was acquired, how it was measured, and whether the local protocol supports comparison with the stated reference interval. A label on an image is not enough to establish that two values from different sequences or scanners are interchangeable.

Use local reference ranges, not borrowed cutoffs

A major source of error in cardiac MRI parametric mapping clinical interpretation is treating a published or remembered threshold as universal. Native T1 values vary with magnetic field strength, pulse sequence, vendor, and heart rate. A value obtained at 1.5 Tesla may not be directly comparable with one obtained at 3.0 Tesla, and a MOLLI acquisition cannot simply be assumed to match a SASHA acquisition.

SCMR consensus guidance emphasizes that local reference ranges for native T1 mapping are mandatory. That recommendation reflects the physics and the implementation: the map is quantitative, but its numbers are shaped by how the measurement is made.

For a clinician reviewing a study, the practical questions are straightforward:

• Was the scan performed at 1.5T or 3.0T?
• Which mapping sequence was used, such as MOLLI or SASHA?
• Does the laboratory maintain a reference range for that specific scanner and protocol?
• Is the patient’s heart rate likely to affect the sequence or its interpretation?
• Are the reported values technically reliable, or is there motion, artifact, or incomplete coverage?

The answers belong in the reading workflow, not only in a technical appendix. If a report gives a T1 value without enough information to understand its reference context, the clinician should be cautious about comparing it with a threshold from another institution.

Local calibration does not make the measurement less useful. It makes the comparison more honest. A laboratory can interpret a value against its own validated range while acknowledging that another site, using another field strength or sequence, may report a different baseline.

Quantitative does not mean universal: the reference range has to belong to the acquisition that produced the number.

ECV: the measurement depends on blood and hematocrit

ECV quantification integrates information from the myocardium and the blood pool before and after contrast administration. It requires native and post-contrast T1 values in both locations, adjusted for the patient’s hematocrit. That hematocrit is part of the calculation, not an optional detail to be filled in later.

This makes ECV a useful example of why a map cannot be interpreted as an isolated image. The result depends on coordinated acquisition and patient-specific data. If the hematocrit is missing, outdated, or not appropriately matched to the examination, the reported ECV may not represent the intended calculation.

When reviewing ECV, I look for a clear chain of inputs:

1. Native T1 measurements are available for myocardium and blood pool.

2. Post-contrast T1 measurements are available for both.

3. Hematocrit is incorporated into the calculation.

4. The resulting percentage is interpreted using the laboratory’s method and reference framework.

ECV can contribute to assessment of expanded extracellular space and diffuse myocardial disease. In a heart failure evaluation, for example, it may add tissue characterization beyond chamber size and ejection fraction. It does not, by itself, determine the cause of heart failure or establish the amount of fibrosis in a way that can be separated from every other influence on the extracellular compartment.

The report should make the method understandable enough for the treating team to judge the result. At minimum, the clinician needs to know that the measurement was calculated from the required myocardial and blood-pool values with hematocrit adjustment. If a number is presented without that context, asking how it was obtained is reasonable clinical practice.

A workflow for reading maps in context

A dependable workflow begins before the images are interpreted. It starts with the referral question and continues through the technical review, the comparison with other findings, and the final report.

1. Define the clinical target

Clarify whether the study is evaluating suspected acute inflammation, diffuse myocardial disease, an infiltrative process, or another tissue-characterization question. This prevents every available map from being treated as equally important in every patient.

2. Confirm the acquisition

Check the field strength, sequence type, and whether the examination includes native T1, T2, T2*, or ECV data. For ECV, confirm the pre- and post-contrast myocardial and blood-pool measurements and the hematocrit input.

3. Assess technical quality

Motion, artifacts, or incomplete myocardial coverage can undermine a result even when the displayed map appears polished. Review the source images and mapping output together. A color scale can make a map easier to scan, but it does not prove that every pixel is reliable.

4. Compare with the appropriate reference

Use the local reference range that matches the scanner and sequence. Avoid applying a single absolute cutoff across vendors, field strengths, or acquisition schemes. If a value is outside the local range, describe that finding in the context of the protocol used.

5. Integrate with the complete examination

Compare mapping results with ventricular function, morphology, edema-sensitive imaging, late gadolinium enhancement, and the clinical presentation. Ask whether the findings support one another, or whether a technical issue or an alternative explanation needs consideration.

6. State the limits clearly

If the acquisition differs from the lab’s validated protocol, if the reference range is unavailable, or if technical quality is limited, say so. A measured value can still be reported, but its interpretive confidence should reflect those constraints.

This sequence keeps the reading grounded. It also helps the treating clinician understand why one measurement is persuasive in a particular case and less decisive in another.

Applying T2 mapping to acute injury and rejection

T2 mapping has a clear practical role when edema is part of the diagnostic question. In acute myocarditis, it can provide quantitative evidence of tissue change that complements the clinical assessment and other MRI sequences. In acute cardiac allograft rejection, it also has diagnostic utility as part of the evaluation.

The wording of the conclusion matters. A raised T2 can support the presence of edema or acute injury; it should not be presented as proof of a specific cause without corroborating evidence. The clinician still has to weigh symptoms, timing, laboratory findings, cardiac function, and the other MRI features.

For transplant clinicians, this is especially important because a mapping result may influence further evaluation, but its meaning depends on the full clinical pathway. The image does not replace the transplant team’s broader assessment. It adds a tissue-level observation to it.

When T2 is within the local reference range, that also needs context. A result that does not show elevated T2 may reduce support for edema in the imaged tissue at that time, but it should be interpreted alongside disease timing, treatment, and image quality. The patient’s clinical course remains central.

Reporting: make the result usable downstream

A useful report tells the next clinician what was measured, how confidently it was measured, and what it contributes to the diagnostic picture. It should avoid unsupported universal cutoffs and avoid implying that a quantitative map alone establishes a diagnosis.

For each reported parameter, include the value and units, the relevant local reference context, and any acquisition limitation that could affect interpretation. For ECV, note that hematocrit was incorporated. For native T1, the sequence and field strength are essential context when comparisons are being made. For T2 mapping, connect the finding to the question of edema or acute injury without overstating specificity.

A concise report can still be clinically rich. For example, it can state that mapping is abnormal relative to the laboratory’s protocol-specific range and explain whether that finding is concordant with the rest of the MRI. If the maps are limited or discordant, the report should describe that plainly rather than smoothing over uncertainty.

Cardiac MRI parametric mapping works best as part of a disciplined tissue-characterization workflow. The immediate habits I recommend are modest: confirm the acquisition before interpreting the threshold, ensure ECV includes hematocrit and blood-pool measurements, and read each map beside the clinical question and the rest of the MRI. Those steps turn a precise-looking number into evidence the care team can actually use.